MHRA Issues Safety Information on StatStrip Ketone Test Strip Lot QC Failures: Recall and Supply Halt Create Roughly Four-Week UK Gap

Overview

On October 9, 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) issued Device Safety Information DSI/2026/013 concerning Nova Biomedical StatStrip ketone test strips. Nova Biomedical recalled specified lots and stopped shipping them because these lots were associated with repeated quality control (QC) failures. The company also required that any subsequent lots that fail QC be withdrawn from use. UK replacement inventory is expected to be unavailable for about four weeks, and point-of-care blood ketone testing capacity may decline progressively. MHRA also set out handling requirements for user facilities and distributors.

On October 16, 2026, MHRA updated the information to add a new lot number to the Field Safety Notice (FSN).

The weight of the notice lies elsewhere: lots, QC and supply were placed in the same document.

Published October 25, 2026, 19:51. Category: Quality, Clinical and Cybersecurity.

What Happened

According to MHRA, Nova Biomedical identified quality problems in specified lots associated with repeated QC failures. On that basis, the company initiated a recall and expressly required that these lots not be used.

There were two further actions beyond the recall. The company placed the affected lots on stop-shipment and further required that other lots be withdrawn from use if they later produce QC failures.

This means available inventory is not fixed. It will contract as the QC results of each lot become known; a quantity sufficient today may not be sufficient tomorrow.

Supply-Side Timing Gap

MHRA states that Nova Biomedical expects UK replacement stock to be unavailable for about four weeks. This creates short-term supply tightness.

Blood ketone testing is used across a wide range of settings: emergency departments, acute inpatient care, paediatrics, emergency and paramedic care, community hospitals, virtual wards, hospital at home, primary care and community nursing. A stockout in one setting will appear simultaneously across these pathways.

Clinical Risk Chain

Blood ketones are a key tool for identifying and monitoring treatment of diabetic ketoacidosis (DKA). NHS guidance states that a blood ketone concentration above 3 mmol/L may indicate DKA and requires emergency assessment. NICE clinical pathways also include blood ketone testing; for children and young people with suspected DKA, near-patient testing is recommended first, and if a near-patient result cannot be obtained, referral should be made to a hospital with paediatric emergency capabilities.

If testing capacity declines, the consequences are measured in delay: delayed identification or exclusion of DKA, delayed escalation and transfer, delayed treatment adjustment and delayed assessment of whether treatment is effective. DKA itself can be life-threatening.

Requirements for User Facilities

MHRA sets out a clear sequence. First, inventory the lots held by the facility, stop use of recalled lots and dispose of them according to local procedures. Non-recalled lots may continue to be used, but must be used according to the instructions for use.

A further point is easily overlooked: if the same lot produces two consecutive QC failures, the lot must be withdrawn from use, the remaining stock disposed of according to local procedures, and another lot or another blood ketone testing method used.

MHRA also warns that current stock levels should not be assumed to last until supply resumes, because further lots may be removed due to QC failures. Facilities should assess existing testing capacity and the expected stockout date, and validate available alternative methods, including other point-of-care devices and laboratory testing. During supply tightness, blood ketone testing should be prioritised for the groups at highest clinical risk: suspected or confirmed DKA, children, acutely unwell patients with type 1 diabetes, and those who need serial monitoring during treatment.

Requirements for Distributors and Channels

Distributors must implement the manufacturer's recall and stop-shipment arrangements, must not supply lots judged nonconforming, and must be prepared to respond to subsequent safety communications. End users must be able to see the DSI and FSN.

These requirements make channel responsibility concrete. A recall does not end with returning goods to the factory; it must be effectively stopped at the end of the distribution chain.

Scope of This Event

This is UK market device safety information concerning specific test strip lots from a specific company and the UK supply situation. It does not constitute a conclusion on any other product, lot or registration application.

What can be taken away is a handling framework: lot-level recall, stop-shipment, dynamic contraction of available inventory based on QC results, and synchronised awareness across channels and end users. This framework does not depend on product category and applies equally to other in vitro diagnostic reagents.

Source and Verification

Source: UK Medicines and Healthcare products Regulatory Agency (MHRA), Nova Biomedical StatStrip ketone test strips: risk of disruption to blood ketone testing due to quality-control failures and supply interruption, DSI/2026/013, published October 9, 2026 and updated October 16, 2026.

https://www.gov.uk/drug-device-alerts/nova-biomedical-statstrip-ketone-test-strips-risk-of-disruption-to-blood-ketone-testing-due-to-quality-control-failures-and-supply-interruption-dsi-slash-2026-slash-013

Verification scope and access date: the full text of the above MHRA Device Safety Information, including the October 16, 2026 supplement, and the publication date of the entry in the MHRA drug and device safety information list were verified. Access date: October 25, 2026. The lot handling requirements, supply timing and clinical thresholds in this article are taken from the original page; no secondary reports were cited.

Applicability note: this article is an interpretation of public regulatory information and does not constitute a conclusion or commitment regarding any specific product, company or registration application. Lot determinations, alternative testing methods and supply arrangements are governed by the official original text and the manufacturer's Field Safety Notice; information may change with subsequent official updates.

Information source: Medicines and Healthcare products Regulatory Agency (MHRA), 2026-10-09.

AIMEILI Regulatory Interpretation

This notice illustrates how a lot-level QC trend can escalate into a public regulatory action, a recall, a stop-shipment and a rolling field safety measure. For manufacturers, distributors, CROs and regulatory affairs teams, the key issue is not only the individual product event but the control system that must detect, contain and communicate lot-specific quality failures across the supply chain.

• QC failure trends are a regulatory trigger. A repeated lot-level QC failure pattern can escalate from a laboratory or manufacturing issue into a Field Safety Corrective Action (FSCA), a recall, a stop-shipment and a public DSI. Manufacturers should treat QC trending, deviation management and CAPA effectiveness as regulatory-affecting controls, not only production metrics.
• The action is rolling, not static. The requirement to withdraw future failing lots means the recall boundary can expand after the initial notice. Lot traceability, distribution records, customer lists and FSN update procedures must support a dynamic field action.
• DSI and FSN are linked communications. The MHRA DSI provides the regulatory alert; the manufacturer FSN provides the operational instructions. Distributors and users need both, and the lot list in the FSN must remain current.
• Alternative methods require validation, not just substitution. MHRA asks facilities to validate alternatives. For manufacturers and laboratories, switching point-of-care devices or laboratory methods without appropriate verification can introduce clinical and compliance risk.
• UK action can signal global review. Although the notice is UK-specific, the underlying QC and supply data may be relevant to other regulators, notified bodies and customers. Global regulatory affairs teams should assess whether similar lots, processes or supplier controls are affected in other markets.

Business Impact

• Manufacturers: potential inventory write-offs, stop-shipment costs, customer service burden and increased regulatory scrutiny. More importantly, the company must maintain rapid lot-level traceability and demonstrate CAPA effectiveness. Repeated QC failures can affect tender eligibility, customer confidence and future registrations or market access.
• Distributors: immediate obligations to quarantine affected stock, stop supply, notify customers, retrieve product where required and document the action for inspections. Contractual liability and reimbursement disputes may follow if nonconforming lots reach users.
• Healthcare providers: need to assess stock, validate alternatives and prioritise testing for suspected or confirmed DKA, children, acutely unwell type 1 diabetes patients and those requiring serial monitoring. Local pathways should prepare for a four-week gap.
• CROs and regulatory affairs teams: should align vigilance, post-market surveillance and technical documentation with the field action. For in vitro diagnostics, lot release, QC records and stability data may come under closer review. Any future submissions should be able to explain how lot-level QC failures are detected, investigated and reported.
• Supply chain planning: single-source test strip supply creates clinical vulnerability. Companies and providers should map stockout scenarios, qualify alternatives and define communication triggers before a DSI is issued.